Jan. 14 at 3:14 AM
$CADL
<Part 1>
CAN-2409 (Pancreatic & Lung Cancer): Clinical trials to date have already demonstrated clear indicators of "systemic immune response activation." If future data can establish a 1:1 correlation between specific cytokine levels or immune cell shifts and clinical treatment response, it will serve as a powerful "Buy" signal. Data proving that "patients possessing this specific marker show a 100% improvement in survival" is an irresistible value proposition that Big Pharma simply cannot refuse.
These additional biomarkers represent the final piece of the puzzle for Candel to prove that their "drug is a product of pure science, not a lottery." The recruitment of world-class experts like Carl H. June, M.D. and Bali Pulendran, Ph.D. for their commercialization strategy in late 2025 can be interpreted as a calculated move to secure a premium valuation at the negotiating table once this data is solidified.
